Allen Lee Cohn
University of Southern California
151 Papers
1.1K Citations
Allen Lee Cohn is an academic researcher from University of Southern California. The author has contributed to research in topics: Bevacizumab & Medicine. The author has an hindex of 35, co-authored 142 publications.
Chat about Author
Papers
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
Heinz-Josef Lenz,Eric Van Cutsem,Shirin Khambata-Ford,Robert J. Mayer,Philip J. Gold,Philip Stella,B. Mirtsching,Allen Lee Cohn,Andrew William Pippas,Nozar Azarnia,Zenta Tsuchihashi,David J. Mauro,Eric K. Rowinsky +12 more
TL;DR: Cetuximab is active and well tolerated in metastatic CRC refractory to irinotecan, oxaliplatin, and fluoropyrimidines and neither EGFR kinase domain mutations nor EGFR gene amplification appear to be essential for response to cetUXimab in this setting.
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Thomas H. Cartwright,Paul R. Kuefler,Allen Lee Cohn,William J. Hyman,Maury Berger,Donald A. Richards,Svetislava J. Vukelja,John E. Nugent,Robert L. Ruxer,Kristi A. Boehm,Lina Asmar +10 more
TL;DR: XELIRI plus cetuximab is a promising regimen that merits further study for first-line mCRC, and 36% of patients remain alive.
Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).
Johanna C. Bendell,Thomas Ervin,Neil Senzer,Donald A. Richards,Irfan Firdaus,A. Craig Lockhart,Allen Lee Cohn,Mansoor N. Saleh,L. Gardner,Peter Sportelli,Cathy Eng +10 more
TL;DR: A prospective, randomized, double-blind, placebo-controlled randomized phase III trial of P-CAP vs. CAP with a primary endpoint of overall survival (OS) in pts with refractory mCRC, which showed improvement in mTTP and mOS.
Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP).
Allen Lee Cohn,T. S. Bekaii-Saab,Johanna C. Bendell,Herbert Hurwitz,Mark Kozloff,Nancy Roach,H. Tezcan,S. Feng,A. Sing,A. Grothey +9 more
TL;DR: BV (Avastin) prolongs progression free (PFS) and overall survival (OS) when added to chemotherapy (CT) in first- or second-line treatment (Tx) of mCRC.
Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.
Vicky Makker,Drew W. Rasco,Nicholas J. Vogelzang,Mark Messing,Marcia S. Brose,Allen Lee Cohn,Carol Aghajanian,Daniel E. Stepan,Corina E. Dutcus,Emmett V. Schmidt,Matthew Guo,Pallavi Sachdev,Robert Shumaker,Matthew H. Taylor +13 more
TL;DR: In this paper, the authors report updated interim results from a phase 1b/2 study of Pembrolizumab (PEM) and Lenvatinib (LEN).